Wall Street analyst estimates for Fennec Pharmaceuticals Inc. (FENC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $0.09 | ||
| 2026-08-11 | $0.05 | $0.02 | +150.0% |
| 2026-05-14 | $0.01 | $-0.02 | +150.0% |
| 2026-03-24 | $-0.17 | $0.03 | -666.7% |
| 2025-11-13 | $-0.02 | $-0.08 | +75.0% |
| 2025-08-14 | $-0.11 | $-0.06 | -83.3% |
| 2025-05-13 | $-0.04 | $-0.12 | +66.7% |
| 2025-03-10 | $-0.06 | $0.56 | -110.7% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $170000 | 0 | $1.5M | $21.3M | $47.5M | $44.6M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | $86000 | $1.3M | $3.2M | $3.8M |
| Gross Profit | 0 | 0 | 0 | 0 | $170000 | 0 | $1.4M | $20.0M | $44.4M | $40.9M |
| Research & Development | $472000 | $1.9M | $5.0M | $5.7M | $5.1M | $5.0M | $3.5M | $56000 | $307000 | $250000 |
| Selling, General & Admin | $2.4M | $5.0M | $5.4M | $7.6M | $12.9M | $12.2M | $20.5M | $32.7M | $41.5M | $46.9M |
| Operating Expenses | $2.9M | $7.0M | $10.4M | $13.3M | $18.1M | $17.2M | $24.2M | $33.1M | $41.9M | $47.2M |
| Operating Income | -$2.9M | -$7.0M | -$10.4M | -$13.3M | -$17.9M | -$17.2M | -$22.7M | -$13.1M | $2.5M | -$6.3M |
| EBITDA | $82000 | -$95000 | $521000 | -$13.1M | -$18.1M | -$17.2M | -$22.6M | -$12.4M | $4.8M | -$7.5M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | $126000 | $978000 | $3.4M | $4.1M | $2.1M |
| Pre-tax Income | -$2.8M | -$7.0M | -$9.9M | -$13.1M | -$18.1M | -$17.3M | -$23.7M | -$16.0M | -$71000 | -$9.6M |
| Income Tax | -$8000 | -$47000 | -$348000 | 0 | 0 | 0 | 0 | 0 | $365000 | $106000 |
| Net Income | -$2.8M | -$7.0M | -$9.9M | -$13.1M | -$18.1M | -$17.3M | -$23.7M | -$16.0M | -$436000 | -$9.7M |
| EPS | $-0.22 | $-0.47 | $-0.52 | $-0.63 | $-0.76 | $-0.67 | $-0.95 | $-0.60 | $-0.02 | $-0.36 |
| EPS (Diluted) | $-0.22 | $-0.47 | $-0.52 | $-0.63 | $-0.76 | $-0.67 | $-0.95 | $-0.60 | $-0.02 | $-0.36 |
| Shares Outstanding (Diluted) | $12.8M | $15.0M | $19.0M | $19.9M | $23.7M | $26.0M | $26.3M | $26.6M | $27.3M | $28.6M |
Price
| Price | $10.55 |
| Market Cap | $366M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AARD · AVTX · BDTX · CRBU · ENTA · EPRX · NAUT
Explore sector: Healthcare · Biotechnology
More sections of FENC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks